STOCK TITAN

Akoya BioSciences, Inc. - AKYA STOCK NEWS

Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.

Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.

In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.

Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.

The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.

Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.

If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.

Rhea-AI Summary
Akoya Biosciences to release Q3 2023 financial results on November 8th
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.1%
Tags
conferences earnings
-
Rhea-AI Summary
Akoya Biosciences highlights industry-leading scale and speed in spatial biology workflows with PhenoCycler-Fusion 2.0 and PhenoImager HT 2.0 upgrades
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.01%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.73%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.4%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.04%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.73%
Tags
none

FAQ

What is the current stock price of Akoya BioSciences (AKYA)?

The current stock price of Akoya BioSciences (AKYA) is $2.99 as of January 30, 2025.

What is the market cap of Akoya BioSciences (AKYA)?

The market cap of Akoya BioSciences (AKYA) is approximately 149.2M.

What does Akoya BioSciences, Inc. do?

Akoya BioSciences, Inc. specializes in spatial biology solutions, enabling advanced tissue analysis and spatial phenotyping for research and clinical diagnostics.

What are Akoya's core products?

Akoya's core products include the PhenoCycler® platform, PhenoImager® instruments, and PhenoCode™ Panels, which support high-parameter tissue analysis and spatial phenotyping.

How did Akoya perform financially in 2023?

For the fiscal year 2023, Akoya's revenue is expected to range between $95.6 million and $96.6 million, showing significant growth compared to the previous year.

Who are some of Akoya's key partners?

Akoya has partnered with notable organizations like Thermo Fisher Scientific, BostonGene, and NeraCare to enhance its spatial biology capabilities and applications.

What recent achievements has Akoya announced?

Recent achievements include a successful partnership with Thermo Fisher Scientific, positive clinical data presentations, and the opening of a new manufacturing facility in Marlborough, MA.

How many publications have cited Akoya's technology?

As of March 2024, Akoya’s technology has been cited in over 1,300 scientific publications.

What is Akoya's financial outlook for 2024?

Akoya projects full-year 2024 revenue growth exceeding 20% and aims to achieve operating cash flow breakeven by year-end.

What is the significance of the new Manufacturing Center of Excellence?

The new facility in Marlborough, MA, will enhance Akoya's operational efficiency, meet growing demand, and improve supply chain management for its spatial biology solutions.

Who should consider working at Akoya BioSciences?

Scientists and software engineers interested in revolutionizing imaging science and advancing spatial biology should consider opportunities at Akoya BioSciences.

How can one contact Akoya BioSciences for more information?

You can contact Akoya BioSciences via email at info@akoyabio.com for more information.
Akoya BioSciences, Inc.

Nasdaq:AKYA

AKYA Rankings

AKYA Stock Data

149.21M
25.63M
11.09%
70.19%
3.24%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
MARLBOROUGH